Introduction
Lovastatin, a 3 HMG-CoA reductase inhibitor, is a new cholesterol-lowering drug that has been reported to cause a transient rise in creatine kinase (CK) in rare cases. Severe rhabdomyolysis has also recently been reported in cardiac transplant patients receiving multiple drugs including cyclosporin and lovastatin.'" 2 We report a case of lovastatin-induced acute rhabdomyolysis after only 3 weeks of therapy in a patient not receiving concomitant immunosuppressive therapy.
Case report
The patient was a 79 year old female with diffuse atherosclerosis involving her coronary, iliac and femoral arteries. In addition, chronic, stable angina pectoris, severe intermittent claudication, systolic hypertension, mild chronic renal insufficiency, hypercholesterolaemia, and hypertriglyceridaemia were present. Her medical regimen included digoxin, nadolol, enalapril, disopyramide, frusemide, nitroglycerine, and gemfibrozil. Four weeks prior to admission she was started on lovastatin, 20 mg daily. Three weeks later she noted the onset of progressive generalized weakness without myalgias and within 5 days she was admitted to the hospital unable to raise herself to a standing position. There was no history of trauma, seizure, fever, or any antecedent viral infection.
On admission, generalized muscle weakness was evident, while no neurological abnormalities were found. She was not in respiratory distress at this time. Her admission creatine kinase (CK) was 16 ,000 IU/l with an MB fraction of 41.5 IU/1. By the fifth hospital day the CK peaked at 148,000 IU/I. The serum aldolase and aspartate transaminase (AST) were elevated. The free thyroxine, serum protein electrophoresis, electrolytes, and complement were normal. The rheumatoid factor and antinuclear antibody tests were negative. Technetium pyrophosphate and gallium scans were negative for myocardial uptake of either agent. An electromyogram revealed myopathic changes in the proximal muscles.
Lovastatin and gemfibrozil were discontinued upon admission. Over the initial week of hospitalization, skeletal muscle strength diminished and her pulmonary vital capacity declined steadily. By the twelfth hospital day endotracheal intubation and mechanical ventilation became necessary. With supportive therapy her muscle strength improved and she was weaned from mechanical ventilatory support. The CK returned to normal by the sixteenth hospital day. A deltoid muscle biopsy ( Figure 1 ) revealed muscle fibre necrosis with histiocytic cell infiltrates. Immunofluorescent stains for IgA, IgG, 1gM, C3, fibrinogen, and albumen were all negative.
Discussion
Drug-induced rhabdomyolysis is extremely rare but has been reported with pentamadine,3 doxylamine, phenylpropanolamine,4 diphenhydramine,5 theophylline,6 halothane,7 and cytarabine.8 Tobert9 reported 17 cases (0.04%) of lovastatin-associated rhabdomyolysis out of approximately 4000 patients participating in several clinical trials with this drug. Five ofthese patients were concomitantly receiving cyclosporin, 6 received gemfibrozil (2 received both cyclosporin and gemfibrozil), 2 received niacin, and 6 received none of these other drugs. Using these numbers, the relative risk for 
